Regeneron Pharmaceuticals (REGN) Construction in Progress (2013 - 2017)

Regeneron Pharmaceuticals' Construction in Progress history runs 5 years deep, the most recent figure standing at $408.9 million for Q4 2017.

• In Q4 2017, Construction in Progress rose 28.2% year-over-year to $408.9 million; the TTM figure through Dec 2017 stood at $408.9 million (up 28.2% YoY), while the FY2017 annual figure was $408.9 million, up 28.2% from the prior year.
• Construction in Progress for Q4 2017 stood at $408.9 million, up from $318.9 million in the prior quarter.
• The five-year high for Construction in Progress was $579.8 million in Q4 2015, with the low at $142.4 million in Q4 2013.
• The 5-year median for Construction in Progress is $408.9 million (2017), against an average of $384.4 million.
• The sharpest annual moves came in 2014 and 2016: Construction in Progress soared 231.69% in 2014, then tumbled 45.0% in 2016.
• Regeneron Pharmaceuticals' Construction in Progress stood at $142.4 million in 2013, then jumped by 231.69% to $472.2 million in 2014, then rose by 22.79% to $579.8 million in 2015, then sank by 45.0% to $318.9 million in 2016, then gained by 28.2% to $408.9 million in 2017.
• Business Quant data shows REGN's Construction in Progress at $408.9 million in Q4 2017, $318.9 million in Q4 2016, and $579.8 million in Q4 2015.